Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report Q3 2017

JANUARY 1 – SEPTEMBER 30, 2017 (compared with the corresponding period a year ago) · Net sales increased 8.2% to SEK 80,601m (74,466) · Operating profit before amortization of acquisition-related intangible assets (EBITA) rose 31% to SEK 8,953m (6,831) · Adjusted operating profit before amortization of acquisition-related intangible assets (EBITA) rose 11% to SEK 9,786m (8,797) · Adjusted EBITA margin increased 0.3 percentage points to 12.1% (11.8) · Adjusted profit before tax rose 5% to SEK 8,562m (8,119) · Profit for the period increased 86% to SEK 5,719m (3,072)

Interim report   January 1 – September 30, 2017

Lower sales and earnings for NCC in the third quarter· Orders received amounted to SEK 12,782 M (12,578) in the third quarter and to SEK 40,695 M (40,239) for the January-September period · Net sales amounted to SEK 13,102 M (13,572) in the third quarter and to SEK 38,290 M (36,415) for the January-September period · Profit after financial items was SEK 365 M (471) in the third quarter and SEK 1,169 M (711) for the January-September period · Profit after tax was SEK 303 M (387) in the third quarter and SEK 975 M (584) for the January-September period · Earnings per share after

Read original

InDex Pharmaceuticals will participate in the United European Gastroenterology Week (UEGW)

October 26, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company will present a poster at the United European Gastroenterology Week (UEGW). UEGW is the largest scientific meeting for gastroenterologists in Europe. The congress is held in Barcelona, Spain on October 28 – November 1, 2017.The poster summarizes the results from a market research study of 148 ulcerative colitis patients in Europe and the US regarding their familiarity with and perceptions of rectally administered medications. Almost all the patients stated that they have used rectally administered

MyFC Holding (publ) interim report July – September 2017

Significant events July – September· Reinforced Group Management: Torbjörn Möller new Chief Operating Officer and Max Rydahl new marketing and sales director · British Signal Special Opportunities new major owner; Handelsbanken Fonder expands ownership · New patent granted in Canada Comment from CEO Björn Westerholm: “The third quarter of the year has been one of execution. We have strengthened our organization and our finances, we have continued the work to commercialize JAQ Hybrid, and we have begun the development of a Lamina REX prototype. The work to industrialize

Tobii AB Interim Report Q3 2017

Tobii AB today reported its results for the third quarter and first nine months 2017. Comment by Tobii’s CEO Henrik Eskilsson: “The quarter was characterized by very strong sales in Tobii Pro. This was a reflection of a favorable underlying market trend and a result of our investments in developing outstanding products and stronger sales channels. Tobii Dynavox’s sales were negatively impacted by transitory effects, but with the launch of two additional new products it is now well-equipped with an expanded, price-differentiated product portfolio. Within Tobii Tech, we continued to

Interim report January – September 2017

CAUTIOUS MARKET IN STOCKHOLM – STABLE MARKET IN THE REST OF SWEDENRevenue increased to SEK 12,457m (11,456) and operating profit increased to SEK 1,731m (1,414). The operating margin increased to 13.9 percent (12.3) Profit before tax increased to SEK 1,958m (1,379). Profit after tax increased to SEK 1,588m (1,066) Return on equity for the past twelve months increased to 39.7 percent (30.7). Earnings per share during the nine-month period increased to SEK 22.40 (14.50) Consolidated cash flow including net investment in properties was SEK 1,868m (1,589) The number of residential

Startup Studios Are An Emerging Trend in Europe

Klopal Startup Studio  shines the light on Europe’s new breed of emerging startup studios, such as eFounders , Klopal, Drukka , Founders.as  and Antai  to name a few. This model of building companies is, particularly in Europe, still in infancy. Regardless, startup studios are already creating international success stories. “Startup studios have quickly made a lasting impact on the European startup scene. A growing amount of software agencies, accelerators and VC

Fortum January-September 2017 Interim Report: Improved results, Hafslund transactions concluded, investment in Uniper

FORTUM CORPORATION JANUARY-SEPTEMBER 2017 INTERIM REPORT 26 OCTOBER 2017 AT 9.00July−September 2017 · Comparable EBITDA EUR 210 (151) million, +39% · Comparable operating profit EUR 94 (58) million, +62% · Operating profit EUR 387 (-6) million, of which EUR 293 (-65) million related to items affecting comparability · Earnings per share EUR 0.40 (-0.03), of which EUR 0.34 (-0.06) related to items affecting comparability, including sales gains of approximately EUR 0.36 related to the Hafslund transactions · Cash flow from operating activities totalled EUR 185 (101) million

Tikkurila's Business Review for January-September 2017

Tikkurila OyjStock Exchange ReleaseOctober 26, 2017 at 9:00 a.m. (CET+1) Tikkurila's Business Review for January-September 2017 Tikkurila's revenue for the third quarter totaled EUR 159.9 million (7-9/2016: EUR 158.0 million). Adjusted operating profit totaled EUR 21.9 (23.7) million, i.e. 13.7 (15.0) percent of revenue. "Third-quarter revenue was at the same level as last year. However, SBU East's revenue increased especially due to improved sales mix and higher sales prices. Refunds paid to customers in Sweden and the lower sales volumes in Finland and Sweden decreased SBU

Revenio Group Corporation: Interim report January 1-September 30, 2017

Revenio Group Corporation, Interim report, October 26, 2017 at 9:00 am Revenio Group Corporation: Interim report January 1-September 30, 2017 Due to an amendment to the Securities Market Act, which came into force on November 26, 2015, the descriptive sections of Revenio's Interim reports Q1/2017 and Q1-Q3/2017 will be shorter and more concise. The table sections will be reported in accordance with previous practices. The figures are unaudited. Revenio Group Corporation has adopted the publication procedure enabled by the Financial Supervisory Authority's Regulations and guidelines

Orkla ASA: Mandatory notification of trade - primary insiders

Canica AS, a related party to Stein Erik Hagen, Chairman of the Board of Orkla, has on 25 October 2017 bought 858,000 shares in Orkla ASA at a price of NOK 82.82 per share. Following this transaction, Hagen and related parties own 250,010,000 shares in Orkla.  Nian AS, a related party to Nils Selte, Member of the Board of Orkla, has on 25 October 2017 bought 3,000 shares in Orkla ASA at a price of NOK 82.82 per share. Following this transaction, Selte and related parties own 24,000 shares in Orkla. Orkla ASAOslo, 26 October 2017Ref.:Investor RelationsElise HeidenreichTel.:

ContextVision AB presents Q3 2017 Financial report

ContextVision establishes unique platform for future growth within digital pathology  STOCKHOLM - October 26, 2017 - ContextVision, a medical technology company specializing in image analysis and artificial intelligence, has heavily invested in developing state-of-the-art competence within artificial intelligence and the development of a first product within digital pathology that will make the diagnosis of prostate cancer both quicker and more accurate. The product will be ready for market by the end of 2018, as previously announced. "The product development is going very well and

Q-FREE – RESULTS FOR THE THIRD QUARTER 2017

Highlights: * 233 MNOK in revenues, up 18% YoY * 5% reduction in operating expenses YoY * 33 MNOK in EBITDA excl. non-recurring items (14.2% margin), up 43 MNOK YoY * 100 MNOK in order intake (not incl. two frame agreements received in the quarter) * 1.2 bn NOK in order backlog, ~190 MNOK scheduled for delivery in Q4-2017 * 129 MNOK in cash at hand, up 26 MNOK QoQ   -The third quarter of 2017 represents the fourth consecutive quarter with YoY revenue growth, strong cost control, EBITDA growth, and EBITDA margin expansion. We are pleased to see that the restructuring

Completion and results of Nixu Corporation’s share offering

Nixu CorporationPress Release 26 October 2017 at 8:35 A.M. Completion and results of Nixu Corporation’s share offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SOUTH AFRICA, SINGAPORE, NEW ZEALAND OR JAPAN. With reference to the share offering of 500,000 – 750,000 shares announced on 25 October 2017 (the “Offering”), Nixu Corporation (the "Company") is pleased to announce that it will issue 750,000 new shares in the Company (the "Offer Shares") to institutional investors. The Offering was

INTERIM REPORT JANUARY – SEPTEMBER 2017

CONTINOUS SUCCESS FOR HiQJANUARY – SEPTEMBER 2017 · Net sales total SEK 1 293.2 (1 199.0) million, an increase with 7.9 per cent · Operating profit (EBIT) is SEK 152.0 (151.4) million, equivalent to an operating margin of 11.8 per cent · Pre-tax profit of SEK 151.2 (151.0) million · Profit after tax of SEK 117.2 (117.6) million · Earnings per share of SEK 2.13 (2.17) · Cash flow from operations of SEK 112.7 (102.1) million · Liquid assets of SEK 154.6 million JULY – SEPTEMBER 2017 · Net sales total SEK 369.3 (352.1) million, an increase with 4.9 per cent ·

Gränges interim report January-September 2017

Strong demand in the third quarter – investing in future growthThird quarter 2017 · Sales volume increased to 93.0 ktonnes (62.8). Organic growth was 4.8 per cent. Net sales were SEK 2,728 million (1,859). Sales volume for the business acquired in 2016 increased to 48.9 ktonnes (21.8). · Adjusted operating profit increased by 25.1 per cent to SEK 227 million (181), which corresponds to an adjusted operating margin of 8.3 per cent (9.7). The business acquired in 2016 is included with SEK 70 million (50). · Profit for the period decreased to SEK 151 million (189). Third quarter

Positive trend in the Norwegian economy ensures strong profits for DNB

DNB recorded profits of NOK 5 648 million in the third quarter of 2017, up NOK 1 568 millionfrom the third quarter of 2016. A solid momentum in the Norwegian economy contributed to lower losses and higher income for the bank. “In many ways, DNB is a reflection of the Norwegian economy. When Norway Ltd. performs well,so does the bank. This is exactly what is happening now. Optimism has got a sound foothold in the Norwegian economy. DNB’s profit performance has improved in all customer segments, ranging from private individuals to the largest companies,” says Rune Bjerke, DNB’s group

Continuous success for HiQ

Net sales for the period January – September increases with 7.9 per cent to a total of SEK 1 293.2 (1 199.0) million. This is a record for HiQ. Operating profit (EBIT) for the first nine months, also this a record, amounts to SEK 152,0 (151,4) million corresponding to an operating margin of 11.8 per cent. Net sales for the third quarter total SEK 369.3 (352.1) million. Operating profit (EBIT) for the third quarter is SEK 38.5 (46.9) million corresponding to an operating margin of 10.4 per cent. Liquid assets at the end of September total SEK 154.6 million. “The third quarter is always

Scandic’s interim report Q3 2017 – Solid development in sales & profits

Third quarter in summary · Net sales increased by 11.1% to 3,974 MSEK (3,577) primarily due to higher RevPAR and more rooms in operation. · Adjusted EBITDA totaled 622 MSEK (547), corresponding to a margin of 15.7% (15.3). · An agreement was signed to acquire a 293-room hotel in central Frankfurt, which will open in early 2018. · Agreements were signed for two new hotels in Copenhagen, totaling 989 rooms, which will open in 2020 and 2021 respectively. · 17 MSEK in capital gain from the sale of a hotel in Finland. · Earnings per share amounted to 3.65 SEK (4.22).

Revenue still growing, operative operating profit improves

SRV GROUP PLC     INTERIM REPORT     26 OCTOBER 2017, AT 8.30Revenue still growing, operative operating profit improves   January–September 2017 in brief: · Revenue increased to EUR 776.9 (555.5 1−9/2016) million (up 40%). Revenue improved because of the revenue growth in Operations in Finland and the greatest revenue growth was seen in housing construction in Finland. · Operative operating profit* amounted to EUR 14.5 (10.9) million (up 33%). Revenue growth in Operations in Finland and the recognition of more developer-contracted housing than in the comparison period had a

Lindab International AB (publ): Lindab assesses strategic alternatives for its non-ventilation related businesses

As communicated earlier, the Board of Lindab has decided to accelerate the strategy with a clearer focus on the ventilation business. As a result, the Board has decided to assess structural alternatives, including a potential divestment, of its non-ventilation related businesses. The non-ventilation related businesses include the Building Systems segment (representing 11% of 2016 sales) and other construction-related businesses with limited strategic value for the ventilation business. In total, the aforementioned businesses under review are estimated to represent approximately 30% of

Interim Report January-September 2017

“The FDA has set a PDUFA target action date for CAM2038 of January 19, 2018. If approved, this would trigger a US commercial launch early next year.”Business highlights third quarter 2017  · NDA submission to FDA for CAM2038 weekly and monthly buprenorphine depots for treatment of opioid dependence. · MAA submission to EMA for CAM2038. · CAM2038 NDA acceptance with Priority Review by FDA. · CAM2038 MAA validation by EMA. · CAM2043 IND submission to FDA. · Phase 3 long-term safety extension study of CAM2038 initiated in patients with chronic non-cancer pain patients. ·

Nomination Committee

In accordance with decision by the Annual General Meeting, the Nomination Committee in Hoist Finance shall consist of four members. The members should be one representative of each of the three largest shareholders, together with the Chairman of the Hoist Finance Board. The members of the Nomination Committee have been appointed based on the ownership structure as per 31 August 2017, and consists of: ·  Jan Andersson, Chairman, appointed by Swedbank Robur Funds;   ·  Per Josefsson, appointed by Carve Capital AB; ·  Rickard Wilson, appointed by Zeres Capital; and ·  Ingrid

There are no items matching the current filter
There are no more items matching the current filter
Back to top